Doctors who treat long COVID are trying to understand the mysterious syndrome that can follow infections, such as why some patients with mild illness experience ongoing breathing problems and why some with severe disease end up with no lung scarring.
Read MoreMultisystem Inflammatory Syndrome in Children (MIS-C) often strikes when many families least expect it – after a child has recovered from COVID-19 infection. Dean Blumberg, chief of pediatric infectious diseases at UC Davis Children’s Hospital, answers common questions about this life-threatening complication.
Read MoreUC Davis Medical Center is now using Pfizer’s new COVID antiviral pill Paxlovid in patients at high risk of COVID complications. The pill, which can be taken at home, has been shown to dramatically decrease the risk of hospitalization and death.
Read MoreWith the highly contagious COVID-19 Omicron variant surging, many people are reconsidering the type of mask they wear. A UC Davis Health infectious diseases expert has advice about when to wear cloth, surgical, N95 or KN95 masks.
Read MoreUC Davis Health pediatrician Michael Lucien and social justice leader Denisha “Coco” Bland will host a free webinar via Zoom to discuss the effects of COVID-19 on African American and Black populations and offer strategies and solutions to help.
Read MoreA new study by infectious disease experts Sarah Waldman and Stuart Cohen shows vaccinated health care workers with breakthrough COVID-19 infections are at a low risk of transmitting the virus to patients and colleagues in a healthcare setting. Infection prevention strategies were key.
Read MoreDean Blumberg, chief of pediatric infectious diseases at UC Davis Children’s Hospital, and general pediatrician Rachel Heidt, will be participating in a virtual Q&A session, “COVID-19 and Vaccines for Children 5-11 years old,” on Thursday, Dec. 2 from 5:30-6:30 p.m.
Read MoreDavid Kessler, the chief science officer and leader in COVID-19 efforts, provided insights on the rise of mental health issues, COVID vaccines for kids, booster shots, the new oral antiviral drugs, and the rare vaccine side effects.
Read MoreA new study shows that mitigation efforts to reduce COVID-19 on the 10 University of California campuses during the fall of 2020 minimized campus transmission and outbreaks and limited spread to surrounding communities.
Read MoreMonoclonal antibody treatments have been shown to reduce COVID-19-related hospitalization or deaths in high-risk patients. But UC Davis Health infectious disease experts explain why they’re not a replacement for the COVID-19 vaccine.
Read MoreUC Davis Health infectious diseases specialist George Thompson answered some commonly asked questions about Merck’s new COVID-19 pill. The medication could be given in the days after COVID-19 symptoms arise to prevent severe disease.
Read MoreUC Davis Health infectious disease experts are concerned the drought in California could lead to an increase in cases of Valley fever, a disease that primarily presents as a respiratory illness.
Read MorePoor air quality caused by wildfire smoke can affect lung health, particularly for those with asthma and other respiratory conditions. UC Davis Health experts have some tips for protecting yourself when it’s smoky outside.
Read MoreThe Sacramento area is seeing more cases of COVID-19 and the highly contagious Delta variant. What does this mean for students who are slated to be back on campus, especially those too young to be vaccinated?
Read MoreA new study confirms the low likelihood that coronavirus contamination on hospital surfaces is infectious. The study is the original report on recovering near-complete SARS-CoV-2 genome sequences directly from surface swabs.
Read MoreThe UC Davis MIND Institute is offering a COVID-19 vaccine clinic for individuals with autism and other neurodevelopmental conditions. The clinic will offer a comfortable experience for families, including sensory support and specially trained staff.
Read MoreUC Davis Health will soon launch a stage 3 clinical trial for a new coronavirus vaccine for children ages 12-17 with the National Institutes of Health (NIH) and Novavax. The two-year study aims to enroll 100 participants.
Read MoreIn the search for potential COVID-19 treatments, UC Davis School of Medicine is recruiting participants for more than 12 clinical trials.
Read MoreNatural mutations of the coronavirus have created two fast-spreading COVID-19 variants. Infectious disease expert Dean Blumberg explains why they are more contagious, how they may affect people, and how we can protect ourselves.
Read MoreParticipants are needed for a new clinical trial at UC Davis Health to test another experimental COVID-19 vaccine that could help address the global pandemic.
Read More